Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes
Generex Provides Update on Dosing of Patients In Phase III Trial of Generex Oral-lyn
July 26th, 2008
Generex Biotechnology Corporation (NasdaqCM:GNBT, www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has initiated dosing of over one hundred patients in the Company's pivotal Phase III clinical trial of, Generex Oral-lynO, its flagship proprietary oral insulin spray product. Dosing of patients is now underway at 31 clinical trial sites in the United States, Canada, Russia, and Ukraine. "We are pleased to report that the Generex Oral-lyn trial is now well underway," said Boris Iossel, President of OSMOS Clinical Research, Inc. (www.osmos.us) of San Francisco, California, the Company's global...
Source: Law & Health Weekly (2008-07-26)
|
